Difference between revisions of "CD166-180"
From Opengenome.net
| Line 76: | Line 76: | ||
<tr> | <tr> | ||
<td><strong> CD177</strong></td> | <td><strong> CD177</strong></td> | ||
| − | <td> </td> | + | <td> 58-64</td> |
| − | <td> </td> | + | <td> NB1 </td> |
| − | <td> </td> | + | <td> Surfaces and secondary granules of neutrophils</td> |
| − | <td> </td> | + | <td> Glycoprotein </td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
<td bgcolor="#cccccc"><strong> CD178</strong></td> | <td bgcolor="#cccccc"><strong> CD178</strong></td> | ||
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Monomer of cell surface form 40; soluble forms 26-30</td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Fas ligand, FasL</td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Constitutive or induced expression on many cell types including T cells, NK cells, microglial cells, neutrophils, nonhematopoietic cells such as retinal and corneal parenchymal cells </td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Not known </td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
<td><strong> CD179a</strong></td> | <td><strong> CD179a</strong></td> | ||
| − | <td> </td> | + | <td> 16-18</td> |
| − | <td> </td> | + | <td> VpreB </td> |
| − | <td> </td> | + | <td> Selectively expressed in pro-B and early pre-B cells </td> |
| − | <td> </td> | + | <td> Associates with CD 179b to form surrogate light chain if the preB cell receptor </td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
<td bgcolor="#cccccc"><strong> CD179b</strong></td> | <td bgcolor="#cccccc"><strong> CD179b</strong></td> | ||
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> 22</td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Lambda5 </td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Selectively expressed in pro-B and early pre-B cells </td> |
| − | <td bgcolor="#cccccc"> </td> | + | <td bgcolor="#cccccc"> Associates with CD 179a to form surrogate light chain if the preB cell receptor </td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
<td><strong> CD180</strong></td> | <td><strong> CD180</strong></td> | ||
| − | <td> </td> | + | <td> 95-105</td> |
| − | <td> </td> | + | <td> RP105, LY64 </td> |
| − | <td> </td> | + | <td> Monocytes, dendritic cells, mantle zone B cells </td> |
| − | <td> </td> | + | <td> Not known </td> |
</tr> | </tr> | ||
</tbody> | </tbody> | ||
</table> | </table> | ||
Latest revision as of 18:14, 12 September 2006
|
CD antigen |
MW.(kDa) |
Synonyms & Properties |
Leukocyte expression |
Function |
| CD166 | 100-105 | BEN, DM-GRASP, KG-CAM, neurolin, SC-1, activated-leukocyte cell-adhesion molecule (ALCAM) | Activated T cells, activated monocytes, epithelium, neurons, fibroblasts | Adhesion molecule that binds to CD6 |
| CD167 | α subunit 54, β subunit 63 | DDR1 (discoidin domain family member 1) | Mainly normal and transformed epithelial cells | Receptor tyrosine kinase activated by various types of collagen |
| CD168 | 85-95 | RHAMM (receptor for hyaluronan-mediated motility) | Some fibroblast cell lines, lymphovytes, hematopoietic progenitor cells and malignant B lymphocytes | Expressed on a hyaluronan-binding receptor that participates in the hyaluronan-dependent motility of thymocytes, lymphocytes, hematopoeitic progenitor cells, and malignant B lymphocytes |
| CD169 | 220 | SIGLEC-1 (sialic acid ctin-1); Sialoadhesion | Macrophages | Mediates cell-cell interactions by binding to sialylated ligands on neutrophils, monocytes, NK cells, B cells, and a subset of CD8+ T cells |
| CD170 | 140 | SIGLEC-5 (sialic acid binding Ig-like lectin-1) | Relatively high levels on neutrophils | May be involved in sialic acid-dependent cell-cell interactions |
| CD171 | 200-230 | L1 cell adhesion molecule | Low to intermediate expression on human lymphoid and myelomonocytic cells including CD4+ T cells, a subset of B cells, monocytes, monocyte-derived dendritic cells, many cells of the central and peripheral nervous system | Cell adhesion molecule that plays a role in the maintenance of pymph node architecture during an immune response |
| CD173 | H2, blood group O antigen | Among hematopoietic cells, present on erythrocytes and CD34+ hematopoietic precursors | Glycoprotein-borne oligosaccharide | |
| CD174 | Lewis Y blood group antigen | Among hematopoietic cells, present on erythrocytes and CD34+ hematopoietic precursors | Glycoprotein-borne oligosaccharide | |
| CD177 | 58-64 | NB1 | Surfaces and secondary granules of neutrophils | Glycoprotein |
| CD178 | Monomer of cell surface form 40; soluble forms 26-30 | Fas ligand, FasL | Constitutive or induced expression on many cell types including T cells, NK cells, microglial cells, neutrophils, nonhematopoietic cells such as retinal and corneal parenchymal cells | Not known |
| CD179a | 16-18 | VpreB | Selectively expressed in pro-B and early pre-B cells | Associates with CD 179b to form surrogate light chain if the preB cell receptor |
| CD179b | 22 | Lambda5 | Selectively expressed in pro-B and early pre-B cells | Associates with CD 179a to form surrogate light chain if the preB cell receptor |
| CD180 | 95-105 | RP105, LY64 | Monocytes, dendritic cells, mantle zone B cells | Not known |
